Equities research analysts forecast that AngioDynamics, Inc. (NASDAQ:ANGO) will report ($0.03) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AngioDynamics’ earnings. AngioDynamics posted earnings of $0.19 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 115.8%. The firm is scheduled to report its next quarterly earnings results on Tuesday, April 7th.
On average, analysts expect that AngioDynamics will report full-year earnings of $0.13 per share for the current fiscal year. For the next year, analysts forecast that the firm will report earnings of $0.26 per share, with EPS estimates ranging from $0.25 to $0.27. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, January 7th. The medical instruments supplier reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. The business had revenue of $70.00 million during the quarter, compared to analysts’ expectations of $71.28 million. AngioDynamics had a return on equity of 3.72% and a net margin of 17.47%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.22 earnings per share.
Shares of ANGO opened at $12.81 on Friday. The business has a 50-day simple moving average of $14.79 and a two-hundred day simple moving average of $16.33. The stock has a market cap of $477.85 million, a price-to-earnings ratio of 8.77 and a beta of 0.69. AngioDynamics has a 52 week low of $12.61 and a 52 week high of $25.48.
Institutional investors and hedge funds have recently modified their holdings of the business. Massachusetts Financial Services Co. MA increased its position in AngioDynamics by 12.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 105,748 shares of the medical instruments supplier’s stock worth $1,948,000 after buying an additional 11,796 shares in the last quarter. Synovus Financial Corp purchased a new stake in AngioDynamics in the third quarter worth about $269,000. Nuveen Asset Management LLC purchased a new stake in AngioDynamics in the second quarter worth about $4,865,000. Assenagon Asset Management S.A. increased its position in AngioDynamics by 421.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 284,962 shares of the medical instruments supplier’s stock worth $4,562,000 after buying an additional 230,262 shares in the last quarter. Finally, Boston Advisors LLC increased its position in AngioDynamics by 60.9% in the third quarter. Boston Advisors LLC now owns 80,116 shares of the medical instruments supplier’s stock worth $1,476,000 after buying an additional 30,336 shares in the last quarter. Institutional investors and hedge funds own 98.99% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
See Also: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.